This post was originally published on this site

[unable to retrieve full-text content]Sorrento Therapeutics (NASDAQ: SRNE) has added another arrow to its COVID-19 quiver. The biotech licensed an adipose-derived mesenchymal stem cell (MSC) treatment from Personalized Stem Cells for …